Zacks Investment Research upgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a hold rating to a buy rating in a report released on Wednesday morning. They currently have $7.00 price objective on the stock.
According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “
Shares of Leap Therapeutics (NASDAQ LPTX) traded down $0.05 during mid-day trading on Wednesday, hitting $6.33. The stock had a trading volume of 82,900 shares, compared to its average volume of 99,600. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). sell-side analysts expect that Leap Therapeutics will post -3.63 earnings per share for the current year.
In related news, COO Augustine Lawlor acquired 1,057,769 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average price of $6.09 per share, with a total value of $6,441,813.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 58.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Leap Therapeutics (LPTX) Upgraded to Buy at Zacks Investment Research” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2018/01/05/leap-therapeutics-lptx-upgraded-to-buy-at-zacks-investment-research.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.